[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Alterome Therapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":69},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":68},"100580305","phase-1-a-study-to-learn-about-study-medicine-alta3263-in-adults-with-advanced-solid-tumors-with-kras-mutations-100580305",false,"NCT06835569","A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations","A Phase 1\u002F1b Multiple Cohort Trial of ALTA3263 in Patients With Advanced Solid Tumors With KRAS Mutations","Inclusion Criteria:\n\n* Histologically confirmed diagnosis of a solid tumor malignancy harboring a KRAS mutation identified through molecular testing (NGS- or PCR-based) with a Clinical Laboratory Improvement Amendments-certified (or equivalent) diagnostic test.\n* Unresectable or metastatic disease.\n* Progressed on, intolerant to, or declined prior standard-of-care therapy (including targeted therapy, if applicable) appropriate to tumor type and stage\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate organ function\n\nExclusion Criteria:\n\n* Prior treatment with a KRAS inhibitor, certain exceptions are described in the full study protocol\n* Known condition that prohibits the ability to swallow or absorb an oral medication.\n\nOther inclusion\u002Fexclusion criteria may apply.","ALL","18 Years",{"count":19,"type":20},448,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.",[26,27,28,29,30],"Cancer","PDAC - Pancreatic Ductal Adenocarcinoma","NSCLC (Non-small Cell Lung Cancer)","CRC (Colorectal Cancer)","Advanced Solid Tumors",[32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55],"KRAS mutation","NSCLC","Non-small cell lung cancer","Colorectal cancer","Pancreatic ductal adenocarcinoma","Colorectal carcinoma","Pancreatic cancer","Pancreatic carcinoma","Solid tumors","KRAS","Mutation","Metastatic","Advanced unresectable","Neoplasms","Neoplasms by Site","Carcinoma","Non-small cell lung carcinoma","Non-small cell lung neoplasm","Pancreatic neoplasm","Lung neoplasm","Colorectal neoplasm","Colon neoplasm","Mutant KRAS","KRAS amplification","RECRUITING","2026-06-08",{"date":59,"type":60},"2026-06-10","ACTUAL",{"date":62,"type":60},"2025-03-05",{"date":64,"type":20},"2029-08",{"name":66,"class":67},"Alterome Therapeutics, Inc.","INDUSTRY",12,""]